| |
Omarigliptin N = 154
|
Placebo N = 153
|
|---|
|
Age, years
|
57.2 ± 8.4
|
58.4 ± 9.4
|
|
Female, n (%)
|
81 (52.6)
|
79 (51.6)
|
|
Race, n (%)
|
|
White
|
116 (75.3)
|
110 (71.9)
|
|
Asian
|
28 (18.2)
|
29 (19.0)
|
|
Black
|
8 (5.2)
|
7 (4.6)
|
|
Multi-racial
|
2 (1.3)
|
6 (3.9)
|
|
Native Hawaiian or other Pacific Island
|
0 (0.0)
|
1 (0.7)
|
|
Ethnicity, n (%)
| | |
|
Not Hispanic or Latino
|
134 (87.0)
|
140 (91.5)
|
|
Hispanic or Latino
|
14 (9.1)
|
5 (3.3)
|
|
Not reported
|
2 (1.3)
|
3 (2.0)
|
|
Body Weight, kg
|
87.8 ± 18.3
|
85.4 ± 21.2
|
|
BMI, kg/m2
|
31.8 ± 6.2
|
30.6 ± 5.8
|
|
HbA1c, %
|
8.5 ± 0.8
|
8.6 ± 0.8
|
|
FPGa, mmol/L
|
10.1 ± 2.3
|
10.2 ± 2.3
|
|
Duration of type 2 diabetes, years
|
9.8 ± 5.3
|
10.4 ± 5.5
|
|
SU status at screening
| | |
|
Glimepiride
|
103 (66.9)
|
104 (68.0)
|
|
SU other than glimepiride
|
51 (33.1)
|
49 (32.0)
|
- Values are mean ± standard deviation unless otherwise noted
-
BMI body mass index, FPG fasting plasma glucose, SU sulfonylurea
-
aTo convert to mg/dL multiply mmol/L value by 18
